Tempus AI IPO
Tradingprice, listing and company profile
IPO price$37.00Price range: $35.00 – $37.00
Deal size$410.7M11,100,000 shares
Valuation$6.1BIPO valuation
- IPO filing
- Roadshow
- Pricing
- First trade
- Quiet period
- Lockup
Performance since IPO
Confirmed share price history
No published trading history yet
IPO recap
Confirmed offering terms
Tempus AI filed IPO documents on May 28, 2024. Confirmed offering terms are shown below.
FiledMay 28
PricingJun 13
First tradeJun 14
Lockup ends—
The short version
Tempus AI has traded publicly since 2024-06-14. This profile covers the final price, share count, proceeds, business model, operating context and key risks.
Key takeaway 1
Tempus priced 11.1 million shares at $37 and began Nasdaq trading on 14 June 2024.
Key takeaway 2
The platform connects genomic testing, clinical data and AI decision support.
Key takeaway 3
Revenue growth must translate into durable margins and healthcare adoption.
Company in detail
What happened at the IPO
Tempus AI priced its initial public offering at $37.00 per share and began trading on 2024-06-14 on the Nasdaq under TEM. The final price, base share count and gross size are the confirmed transaction terms; they are separate from later market performance.
The deal included 11,100,000 base shares and an over-allotment option for 1,665,000 additional shares. The offering consisted of new Class A common stock; preferred shares converted in connection with the IPO.
Company and products
Tempus AI is Precision-medicine technology company combining clinical data, diagnostics and AI. Its core offering includes Genomic tests, clinical decision support, data products and AI tools for clinicians and researchers.
Tempus sells into healthcare providers, pharmaceutical research and the growing market for data-informed treatment decisions. The company’s route to scale therefore depends on both product demand and the operating discipline needed to serve that demand.
Capital, ownership and use of proceeds
The registration materials described the capital structure and the distinction between new shares and shares sold by existing holders. Research and development, commercial expansion, working capital and general corporate purposes.
The headline gross offering value is not the same as cash retained by the issuer. Underwriting discounts, offering expenses, selling-stockholder proceeds and any concurrent securities must be read separately in the final prospectus.
Financial and operating lens
FY2023 revenue: $531.8M. Revenue disclosed in the registration materials for the year ended 31 December 2023.
The public-market analysis should connect this operating measure to revenue quality, cash conversion, customer or user retention and the cost of expanding the platform. IPO proceeds can extend the runway, but they do not remove execution risk.
Why this IPO matters
Tempus was a public-market test of whether a large clinical data asset can become a repeatable, profitable software and diagnostics platform.
The main questions after the first trade are whether the company can deliver on its stated growth plan, preserve service quality and turn the IPO story into durable public-company results.
- Clinical validation, data governance and payer economics are as important as model performance.
Operating metrics
FY2023 revenue
$531.8MRevenue disclosed in the registration materials for the year ended 31 December 2023.
Dec 31, 2023Company profile
- Founded
- 2015
- Legal name
- Tempus AI, Inc.
- Listing
- Nasdaq · TEM
- Headquarters
- Chicago, Illinois, United States
- Business
- Precision-medicine technology company combining clinical data, diagnostics and AI.
- Products
- Genomic tests, clinical decision support, data products and AI tools for clinicians and researchers.
- IPO structure
- The offering consisted of new Class A common stock; preferred shares converted in connection with the IPO.
- Use of proceeds
- Research and development, commercial expansion, working capital and general corporate purposes.
- First trade
- 2024-06-14
- Employees
- No published figure
Timeline
- Public registration filed
Tempus AI moved from private preparation into a public registration process. Filing terms were preliminary and subject to later pricing.
- IPO priced
Tempus AI announced a final price of $37.00 per share for the base offering.
- First trading day
The shares began trading on Nasdaq under TEM.
- Closing confirmed
The issuer confirmed completion of the offering and the final capital-market structure.
FY2023 revenue
$531.8MRevenue disclosed in the registration materials for the year ended 31 December 2023.
Base shares offered
11,100,000Base deal size at the final price; the over-allotment option is shown separately.
Final IPO price
$37.00per shareFinal public offering price announced on 2024-06-13; this is the offer price, not a current market quote.
Employees
—No published figure
Net income
-$196.7MFY2023
Operating cash flow
—No published figure
Revenue
Reported financial periods · USD
$531.8MFY2023
FY2023
Hover, tap or use the arrow keys
Financial figures by period
| Period | Revenue | As of |
|---|---|---|
| FY2023 | $531,800,000.00 | Jun 13, 2024 |
Net income
Reported financial periods · USD
-$196.7MFY2023
FY2023
Hover, tap or use the arrow keys
Financial figures by period
| Period | Net income | As of |
|---|---|---|
| FY2023 | -$196,700,000.00 | Jun 13, 2024 |
Valuation & peers
Price-to-sales, revenue growth and gross margin
Comparable metrics unavailableComparable company figures for the same date are not available.
Revenue growth (%)
| Company | P/S | Growth | GM |
|---|---|---|---|
| Tempus AI | — | — | — |
| No published peer comparison | |||
Context: Private financing valuations and modeled market values do not establish an IPO valuation. Revenue run-rate is not used here to calculate a price-to-sales ratio.
Private valuation and funding details
Final IPO price
$37.00 per shareFinal public offering price announced on 2024-06-13; this is the offer price, not a current market quote.
Base shares offered
11,100,000Base deal size at the final price; the over-allotment option is shown separately.
Gross base offering
$410.7MGross base offering value calculated from the disclosed base share count and IPO price; it is not net proceeds.
IpoHub score
How we score—Not rated
Balance sheet—
Growth—
Community—
Profitability—
Valuation—
Individual category scores are not available.
Where the money goes
$410.7MIPO raise
Use of proceeds—
Allocation percentages—
Net proceeds—
See the reported use of IPO proceeds below.
Reported use of proceeds
- use
- Research and development, commercial expansion, working capital and general corporate purposes.
- structure
- The offering consisted of new Class A common stock; preferred shares converted in connection with the IPO.
Key risks
Editorial analysisClinical adoption
Healthcare workflows and reimbursement can slow adoption of new diagnostic and AI tools.
Data governance
Clinical data requires privacy, consent, security and quality controls.
Research cycles
Pharma and clinical partnerships can have long, uneven sales cycles.
Losses and dilution
The company has invested heavily in growth and may need further capital.
Final deal terms
- Ticker
- TEM
- Exchange
- Nasdaq
- IPO valuation
- $6.1B
- IPO price
- $37.00
- Price range
- $35.00 – $37.00
- Pricing date
- Jun 13, 2024
- First trading day
- Jun 14, 2024
- Shares offered
- 11,100,000
- Deal size
- $410.7M
- Underwriters
- Not confirmed
- Greenshoe shares
- 1,665,000
- Lockup
- Not confirmed
- Quiet period expirations
- Not confirmed
Tempus AI IPO: where and how to invest
Where can I invest in the Tempus AI IPO?
Tempus AI shares have a confirmed trading start on Nasdaq under the ticker TEM. You can buy through a broker that supports that market and makes the shares available to your account. Check the venue, fees and current quote; the market price can differ from the original IPO offer price.
Can I buy Tempus AI shares now?
Tempus AI's public trading start is confirmed. Whether you can buy the stock in your account depends on your broker's market access and account rules. A stock-market order buys at available market prices; it is not an IPO allocation at the original offering price.
When is the Tempus AI IPO?
Tempus AI's confirmed first trading day was Jun 14, 2024. The offering was priced on Jun 13, 2024.
What is the Tempus AI IPO share price?
Tempus AI's confirmed IPO offer price is $37.00 per share. This is the offering price, not a live stock-market quote.
What is Tempus AI's stock ticker and exchange?
The ticker recorded in this profile is TEM. The exchange recorded here is Nasdaq.
Can I buy Tempus AI shares before the IPO?
The Tempus AI offering tracked here already has a confirmed trading start. Buying on the stock market now is therefore not a pre-IPO investment. Check the current quote and available share class with your broker.
Where can I find the Tempus AI IPO prospectus?
Check Tempus AI's official investor-relations announcements and publications from the relevant regulator and exchange. A confidential submission or an announcement about it is not a publicly available prospectus. Before subscribing, read the final prospectus for the risks, price, share class and offering terms.
More questions about the Tempus AI IPO
What does Tempus AI do?
It combines genomic testing, clinical data and AI tools for precision medicine.
What was the IPO price?
Tempus priced its Class A shares at $37 per share.
Who buys the products?
Healthcare providers, life-science companies and research partners are key customer groups.
What is the main risk?
Clinical adoption, reimbursement, data governance and continued operating losses.
Similar IPOs
All IPOs →Not investment advice. Private market prices are dated model estimates. Community votes are not a recommendation.